Core Viewpoint - The stock of 3SBio surged over 10% to HKD 30.5 following Pfizer's registration of two global Phase III clinical trials for the PD-1/VEGF dual antibody PF-08634404 (SSGJ-707) on Clinicaltrials.gov [1] Group 1: Clinical Trials - Pfizer registered two Phase III clinical trials for PF-08634404, targeting advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer [1] - The NSCLC trial aims to enroll 1,500 patients and is expected to complete preliminary results by February 2029, focusing on progression-free survival (PFS) and overall survival (OS) as primary endpoints [1] - The colorectal cancer trial plans to enroll 800 patients, with preliminary results expected by March 2030, comparing against bevacizumab plus chemotherapy, also using OS and PFS as primary endpoints [1] Group 2: Financial Aspects - In May 2025, Pfizer will pay 3SBio a total of USD 1.25 billion upfront, with an additional USD 4.8 billion in milestone payments and a double-digit percentage of sales for the PD-1/VEGF dual antibody [1]
港股异动丨三生制药大涨超10%，合作方辉瑞启动PD-1/VEGF双抗两项全球三期临床